Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financially-troubled Scotia hit by regulatory problems

This article was originally published in Clinica

Executive Summary

The continued survival of Scotia Holdings is in doubt after its key product, Foscan, a light-sensitive drug to treat advanced head and neck cancer tumours, unexpectedly failed to receive approval from the US FDA. Scotia, which now faces severe financial difficulties, is reviewing options for the company, which could include a merger, a disposal or fundraising. Shares in the UK company fell around 60% to 47.5p ($0.7) on the news, before plunging further to finish at just above 24p as Clinica went to press. This compares with a year-high of 230p in March.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074740

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel